| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC22623 | Resminostat | A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM. |
|
| DC24014 | D77 | A potent inhibitor of HIV-1 integrase-LEDGF/p75 interaction. |
|
| DC22379 | LDN-27219 Featured | A potent inhibitor of hTGase (Tissue transglutaminase) with IC50 of 0.8 uM. |
|
| DC23954 | ISO-1 Featured | ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC50 of 7 μM. |
|
| DC22656 | MM-401 Featured | A potent inhibitor of MLL1/WDR5 protein-protein interaction with IC50 of 0.9 nM. |
|
| DC22621 | Elacridar hydrochloride Featured | Elacridar Hcl (GF120918; GW0918) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.IC50 value:Target: P-glycoprotein In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects. |
|
| DC25000 | CUDA | A potent inhibitor of sEH (soluble epoxide hydrolase) with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. |
|
| DC25028 | AUDA Featured | A potent inhibitor of sEH (soluble epoxide hydrolase) with IC50 of 18 nM and 69 nM for mouse sEH and human sEH, respectively. |
|
| DC11674 | PF-DcpSi | A potent inhibitor of the mRNA decapping scavenger enzyme (DcpS) with IC50 of 0.11 nM. |
|
| DC22814 | CEP-751 | A potent inhibitor of TrkA with IC50 of 2.9 nM, also inhibits TrkB, TrkC. |
|
| DC7010 | Cyclosporin H Featured | A potent inhibitor of tumor promoting phorbol ester TPA/PMA and inhibitor of Ca2+/calmodulin dependent EF-2 phosphorylation |
|
| DC24039 | BoNT-IN-1 | A potent inhibitors of Botulinum Neurotoxin A (BoNT) Light Chain with IC50 of 0.9 uM.. |
|
| DC24021 | Integrin-IN-27 | A potent integrin αvβ3 antagonist with IC50 of 18 nM. |
|
| DC11944 | VU714 | A potent inwardly rectifying K+ channel Kir7.1 inhibitor with IC50 of 5.6 uM in T1+ flux assays. |
|
| DC11753 | BL-1249 Featured | BL-1249 is a nonsteroidal anti-inflammatory drug (NSAID) and a potassium channel activator. BL-1249 exhibits more selective for the bladder (EC50 of 1.26 μM) than vascular tissue (EC50 of 21.0 μM). BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively |
|
| DC11943 | MRT2000769 | A potent Kir7.1 inhibitor with IC50 of 2.0 uM, induces long-lasting uterine contractility similar to those observed with VU590.. |
|
| DC22956 | VU0405601 | A potent Kv11.1 (hERG) channel allosteric modulator that protects cardiac tissue from hERG-related drug-induced arrhythmias. |
|
| DC23571 | NS5806 Featured | NS5806 is a potent potassium current activator, increases KV4.3/KChIP2 peak current amplitudes with an EC50 of 5.3 μM. NS5806 slows KV4.3 and KV4.2 current dacay in channel complexes containing KChIP2[1]. |
|
| DC23029 | U 74389G maleate | A potent lipid peroxidation inhibitor that has antishock and endothelial protective actions. |
|
| DC23951 | Cevimeline hydrochloride Featured | Cevimeline HCl is a cholinergic agonist that binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands, and increase tone of the smooth muscle in the GI and urinary tracts. |
|
| DC23950 | Cevimeline Featured | Cevimeline is a parasympathomimetic and muscarinic agonist that affects M1 and M3 receptors. It is used in the treatment of dry mouth and Sjögren's syndrome. Cevimeline has also been shown to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy. |
|
| DC20484 | Otaplimastat | A potent matrix metalloproteinase (MMP) inhibitor.. |
|
| DC11834 | AM-6761 | A potent MDM2-p53 interaction inhibitor with remarkable biochemical (HTRF IC50=0.1 nM), cellular potency (SJSA-1 EdU IC50=16 nM), and favorable pharmacokinetic properties. |
|
| DC11836 | AM-8735 | A potent MDM2-p53 interaction inhibitor with remarkable biochemical (HTRF IC50=0.4 nM), cellular potency (SJSA-1 EdU IC50=25 nM), and favorable pharmacokinetic properties. |
|
| DC22894 | SHU-9119 Featured | A potent melanocortin MC3 and MC4 receptor antagonist with IC50 of 0.23 nM and 0.06 nM, respectively. |
|
| DC21341 | MPT0B098 | A potent microtubule inhibitor that not only inhibits the expression levels of HIF-1α protein but also destabilizes HIF-1α mRNA. |
|
| DC11883 | Adarigiline | A potent monoamine oxidase B (MAO-B) inhibitor.. |
|
| DC24045 | T338C Src-IN-2 | A potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM. |
|
| DC24044 | T338C Src-IN-1 | A potent mutant Src T338C inhibitor with IC50 of 111 nM. |
|
| DC21776 | Candoxatrilat | A potent neutral endopeptidase EC 3.4.24.11 (atriopeptidase) inhibitor that increases endogenous ANF levels and produces natriuretic and diuretic responses intravenously in mice.. |
|
